Acute lymphoblastic leukemia differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 8: Line 8:
The following table differentiates acute lymphoblastic leukemia from other leukemias that may present with similar clinical features such as [[fever]], [[fatigue]], [[weight loss]], recurrent [[infections]] and elevated [[leukocyte counts]]. The following are the differentials:
The following table differentiates acute lymphoblastic leukemia from other leukemias that may present with similar clinical features such as [[fever]], [[fatigue]], [[weight loss]], recurrent [[infections]] and elevated [[leukocyte counts]]. The following are the differentials:


{| class="wikitable"
{|  
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Characteristic
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Causes
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Laboratory abnormalities
! colspan="11" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical Manifestation
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Physical examination
! colspan="3" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Laboratory Findings
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Therapy
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard diagnosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other associations
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings
|-
|-
|[[Acute myeloid leukemia|'''Acute myeloid leukemia''']]  
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Demography
|
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History
* [[Chromosomal]] instability
! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms
* Sporadic [[mutations]]
! colspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Signs
* Prior exposure to [[benzene]]
|-
* Prior exposure to alkylating agents
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Constitutional symptoms
* Prior exposure to [[Topoisomerase II|topoisomerase II inhibitors]]
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Weight
* [[Germline]] ''[[RUNX1]]'' [[mutation]]
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Bleeding
|
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Abdominal Pain
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Vital sign
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Jaundice
! align="center" style="background:#4479BA; color: #FFFFFF;" + |LAP
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
|-
! align="center" style="background:#DCDCDC;" + |[[Acute myelogenous leukemia]]<ref name="pmid30410824">{{cite journal |vauthors=Saif A, Kazmi SFA, Naseem R, Shah H, Butt MO |title=Acute Myeloid Leukemia: Is That All There Is? |journal=Cureus |volume=10 |issue=8 |pages=e3198 |date=August 2018 |pmid=30410824 |doi=10.7759/cureus.3198 |url=}}</ref><ref name="pmid23526416">{{cite journal |vauthors=Estey EH |title=Acute myeloid leukemia: 2013 update on risk-stratification and management |journal=Am. J. Hematol. |volume=88 |issue=4 |pages=318–27 |date=April 2013 |pmid=23526416 |doi=10.1002/ajh.23404 |url=}}</ref>
| align="left" style="background:#F5F5F5;" + |
* Clonal proliferation of malignant myeloid blast cells in the marrow
* Genetic abnormalities t(8;21), inv(16), and t(15;17)
| align="left" style="background:#F5F5F5;" + |
* The most common type of acute leukemia in adults
* Median age of 63 years old
* More in [[congenital]] disorders such as  [[Down syndrome]], [[Bloom syndrome]]
| align="left" style="background:#F5F5F5;" + |
* [[Smoking]], previous [[chemotherapy]] or [[radiation therapy]], [[myelodysplastic syndrome]], and exposure to the chemical [[benzene]]
| align="left" style="background:#F5F5F5;" + |
* [[Fatigue]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | –
| align="left" style="background:#F5F5F5;" + |
* [[Fever]]
| align="center" style="background:#F5F5F5;" + | –
| align="center" style="background:#F5F5F5;" + |Rare
| align="center" style="background:#F5F5F5;" + |Mild and asymptomatic
| align="left" style="background:#F5F5F5;" + |
* Bone [[tenderness]]
* [[Dyspnea]]
* Leukemia cutis
* Swelling of the [[Gingiva|gums]]
* Chloroma
| align="left" style="background:#F5F5F5;" + |
* [[Anemia]]
* [[Anemia]]
* [[Thrombocytopenia]]
* [[Thrombocytopenia]]
* [[Neutropenia]]
* [[Leukocytosis]] or [[leukopenia]]
* Elevated [[LDH]]
| align="left" style="background:#F5F5F5;" + |
* Elevated [[uric acid]]
* Leukemic blasts
* Elevated [[phosphorus]]  
* Positive [[Auer rod|Auer rods]]
* Elevated [[potassium]]
| align="center" style="background:#F5F5F5;" + |NA
* Low [[calcium]]
| align="left" style="background:#F5F5F5;" + |
* Greater than 20% [[myeloblasts]] on [[bone marrow]] aspirate<ref name="pmid27895058">{{cite journal| author=Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T et al.| title=Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. | journal=Blood | year= 2017 | volume= 129 | issue= 4 | pages= 424-447 | pmid=27895058 | doi=10.1182/blood-2016-08-733196 | pmc=5291965 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27895058  }} </ref>
* [[Flow cytometry]] > 20% blasts of [[myeloid]] lineage
|
| align="left" style="background:#F5F5F5;" + |
* [[Pyrexia]]
* Persistent or frequent [[infections]]
* Evidence of [[infection]]
* Fatal within weeks or months if left untreated
|-
! align="center" style="background:#DCDCDC;" + |[[Acute lymphoblastic leukemia]]<ref name="pmid30302234">{{cite journal |vauthors=Sawalha Y, Advani AS |title=Management of older adults with acute lymphoblastic leukemia: challenges & current approaches |journal=Int J Hematol Oncol |volume=7 |issue=1 |pages=IJH02 |date=March 2018 |pmid=30302234 |pmc=6176956 |doi=10.2217/ijh-2017-0023 |url=}}</ref><ref name="pmid23841506">{{cite journal |vauthors=Portell CA, Advani AS |title=Novel targeted therapies in acute lymphoblastic leukemia |journal=Leuk. Lymphoma |volume=55 |issue=4 |pages=737–48 |date=April 2014 |pmid=23841506 |doi=10.3109/10428194.2013.823493 |url=}}</ref>
| align="left" style="background:#F5F5F5;" + |
* Arrest of  [[lymphoblasts]]
* Chromosomal translocations: t(9;22) , t(12;21), t(5;14), t(1;19)
| align="left" style="background:#F5F5F5;" + |
* The most common form of cancer in children
*Peak 2-5 years of age
*Boys > girls
| align="left" style="background:#F5F5F5;" + |
* History of [[cancer]]
* History of drug exposure
| align="left" style="background:#F5F5F5;" + |
* Generalized weakness and [[Fatigue (physical)|fatigue]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | –
| align="left" style="background:#F5F5F5;" + |
* [[Fever]]
| align="center" style="background:#F5F5F5;" + | –
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="left" style="background:#F5F5F5;" + |
* Musculoskeletal pain
* [[Dyspnea]]
* [[Pallor]]
* [[Pallor]]
* [[Mucosal]] [[bleeding]] (less common than in [[acute promyelocytic leukemia]])
* [[Papilledema]]
* [[Bruising]] (less common than in [[acute promyelocytic leukemia]])
* [[Meningism|Nuchal rigidity]]
|
* [[Cranial nerve palsy]]
* [[Cytarabine]]
* [[Testicle|Testicular]] enlargement
* [[Anthracycline]]
* [[Mediastinal mass]]  
* [[Enasidenib]]
| align="left" style="background:#F5F5F5;" + |
* [[Liposomal]] [[daunorubicin]] plus [[cytarabine]]
* [[Anemia]]
* [[Gemtuzumab ozogamicin|Gemtuzumab ozogamycin]]
* [[Thrombocytopenia]]
* [[Midostaurin]]
* Normal or slightly increased [[White blood cells|WBC]] counts 
* [[Enasidenib]]
| align="left" style="background:#F5F5F5;" + |
* Ivosidenib
* [[Lymphoblast|Lymphoblasts]]  
* [[Stem cell transplant]]
* Atypical cells
|
| align="center" style="background:#F5F5F5;" + |NA
* Variable [[prognosis]] based on [[cytogenetic]] and molecular profile
| align="left" style="background:#F5F5F5;" + |
* Five new [[Food and Drug Administration|FDA]]-approved therapies became available in 2017-2018
* [[Bone marrow examination|Bone marrow biopsy]]
| align="left" style="background:#F5F5F5;" + |
* [[CNS]] involvement
|-
|-
|[[Acute promyelocytic leukemia|'''Acute promyelocytic leukemia''']]
! align="center" style="background:#DCDCDC;" + |[[Chronic myelogenous leukemia]]<ref name="pmid25814082">{{cite journal |vauthors=Saußele S, Silver RT |title=Management of chronic myeloid leukemia in blast crisis |journal=Ann. Hematol. |volume=94 Suppl 2 |issue= |pages=S159–65 |date=April 2015 |pmid=25814082 |doi=10.1007/s00277-015-2324-0 |url=}}</ref><ref name="pmid30285354">{{cite journal |vauthors=Eden RE, Coviello JM |title= |journal= |volume= |issue= |pages= |date= |pmid=30285354 |doi= |url=}}</ref>
|
| align="left" style="background:#F5F5F5;" + |
* Prior exposure to alkylating agents
* Dysregulated production and uncontrolled proliferation of mature and maturing [[Granulocyte|granulocytes]]
* Prior exposure to [[topoisomerase II]] inhibitors
* [[BCR/ABL|BCR-ABL1]] fusion gene
* [[Chromosomal translocation|Translocation]] between [[Chromosome 15 (human)|chromosomes 15]] and [[Chromosome 17 (human)|17]]
* [[Dominance relationship|Autosomal dominant]] mutation
* Creation of PML-RAR''alpha'' [[gene]] product
| align="left" style="background:#F5F5F5;" + |
* Differentiation block in [[myeloid cells]]
* Median age 50 years old
|
| align="center" style="background:#F5F5F5;" + |
* Low [[white blood cell]] count (typically)
| align="left" style="background:#F5F5F5;" + |
* Generalized [[Muscle weakness|weakness]] and [[Fatigue (physical)|fatigue]]
* [[Satiety|Early satiety]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Abdominal fullness
| align="left" style="background:#F5F5F5;" + |
* Normal
| align="center" style="background:#F5F5F5;" + | –
| align="center" style="background:#F5F5F5;" + | –
| align="center" style="background:#F5F5F5;" + | +
| align="left" style="background:#F5F5F5;" + |
*Asymptomatic
*[[Blast crisis]] resembling acute leukemia
*Excessive [[Perspiration|sweating]]
* [[Papilledema]]
* [[Tenderness]] over the lower [[sternum]]
| align="left" style="background:#F5F5F5;" + |
* [[Anemia]]  
* [[Anemia]]  
* [[Neutropenia]]
* [[White blood cells|WBC]] > 100,000/microL
* [[Thrombocytopenia]]  
* Absolute [[basophilia]] and [[eosinophilia]]  
* Low [[fibrinogen]]
* [[Platelet|Plt]] > 600,000 to 700,000/microL
* Elevated prothrombin time (PT)
| align="left" style="background:#F5F5F5;" + |
* Elevated partial thromboplastin time (PTT)
* All cells of the neutrophilic series, from [[Myeloblast|myeloblasts]] to mature [[Neutrophil|neutrophils]]
|
* [[Myelocyte]] bulge
* [[Mucosal bleeding]]
| align="left" style="background:#F5F5F5;" + |
* [[Petechiae]]
* Low [[leukocyte alkaline phosphatase]]
* [[Ecchymoses]]
* High [[uric acid]]
* Evidence of [[infection]]
| align="left" style="background:#F5F5F5;" + |
* [[Pallor]]
* [[Bone marrow examination|Bone marrow biopsy]]
* [[Thrombosis]]
| align="left" style="background:#F5F5F5;" + |
|
* Acute [[Gout|gouty arthritis]]
* [[All-trans retinoic acid|All-''trans'' retinoic acid]] (ATRA)
* Venous obstruction
* Arsenic trioxide
|-
* [[Cytarabine]]
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
* [[Anthracycline]]
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology
|
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Demography
* Presence of [[Auer rods]] in promyelocytes
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
* High risk for early death from [[hemorrhagic]] complications<ref name="pmid21993679">{{cite journal| author=McClellan JS, Kohrt HE, Coutre S, Gotlib JR, Majeti R, Alizadeh AA et al.| title=Treatment advances have not improved the early death rate in acute promyelocytic leukemia. | journal=Haematologica | year= 2012 | volume= 97 | issue= 1 | pages= 133-6 | pmid=21993679 | doi=10.3324/haematol.2011.046490 | pmc=3248942 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21993679  }} </ref>
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Constitutional symptoms
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Weight
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Abdominal Pain
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Vital sign
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Jaundice
! align="center" style="background:#4479BA; color: #FFFFFF;" + |LAP
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard diagnosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings
|-
|-
|[[Acute lymphoblastic leukemia|'''Acute lymphoblastic leukemia''']]
! align="center" style="background:#DCDCDC;" + |'''Chronic lymphocytic leukemia'''<ref name="pmid266906142">{{cite journal |vauthors=Rai KR, Jain P |title=Chronic lymphocytic leukemia (CLL)-Then and now |journal=Am. J. Hematol. |volume=91 |issue=3 |pages=330–40 |date=March 2016 |pmid=26690614 |doi=10.1002/ajh.24282 |url=}}</ref>
|
| align="left" style="background:#F5F5F5;" + |
* [[Chromosomal]] instability
* Progressive accumulation of monoclonal [[B cell|B lymphocytes]]
* Sporadic [[mutations]]
| align="left" style="background:#F5F5F5;" + |
|
* The most common leukemia in adults in western countries
* M > F
* Median age 70 years old
| align="left" style="background:#F5F5F5;" + |
* Positive family history
* Exposure to [[Herbicide|herbicides]] or [[Insecticide|insecticides]]
| align="left" style="background:#F5F5F5;" + |
* Generalized [[weakness]]
* [[Anorexia]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="left" style="background:#F5F5F5;" + |
* [[Fever]]
| align="center" style="background:#F5F5F5;" + | –
| align="center" style="background:#F5F5F5;" + | +
The most common abnormal finding
| align="center" style="background:#F5F5F5;" + | +
| align="left" style="background:#F5F5F5;" + |
* [[Skin lesion|Skin lesions]] (leukemia cutis)
* [[Sleep hyperhidrosis|Night sweats]]
* [[Muscle wasting]]
| align="left" style="background:#F5F5F5;" + |
* [[Anemia]]
* [[Anemia]]
* [[Thrombocytopenia]]
* [[Thrombocytopenia]]
* Absolute [[lymphocytosis]] >5000 cells/μl
* [[Neutropenia]]
* [[Neutropenia]]
* Elevated [[LDH]]
| align="left" style="background:#F5F5F5;" + |
* Elevated [[uric acid]]
* Presence of smudge cells
* Elevated [[phosphorus]]  
* Monoclonality of [[Light chain|kappa]] and [[Lambda (anatomy)|lambda]] producing [[B cell|B cells]]
* Elevated [[potassium]]
* Express [[CD19]], [[CD20]], [[CD23]], and [[CD5]] on the [[cell]] surface
* Low [[calcium]]
| align="left" style="background:#F5F5F5;" + |
* Greater than 20% [[lymphoblasts]] on [[bone marrow]] aspirate
* Positive direct antiglobulin (Coombs) test
|
* [[Hypogammaglobulinemia]]
* [[Neurological|Neurologic]] deficits
* Elevated levels of serum [[lactate dehydrogenase]] and [[beta-2 microglobulin]]
* [[Pallor]]
| align="left" style="background:#F5F5F5;" + |
* [[Lymphadenopathy]]
* [[Flow cytometry]] of the [[Venous blood|peripheral blood]]
|
| align="left" style="background:#F5F5F5;" + |
* HyperCVAD ([[cyclophosphamide]], [[vincristine]], [[doxorubicin]], [[dexamethasone]])<ref name="pmid28665419">{{cite journal| author=Terwilliger T, Abdul-Hay M| title=Acute lymphoblastic leukemia: a comprehensive review and 2017 update. | journal=Blood Cancer J | year= 2017 | volume= 7 | issue= 6 | pages= e577 | pmid=28665419 | doi=10.1038/bcj.2017.53 | pmc=5520400 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28665419  }} </ref>
* Extranodal involvement of [[skin]], [[kidney]], [[lung]], [[Spinal cord|spine]]
* R-HyperCVAD (inclusion of [[rituximab]])
* [[Membranoproliferative glomerulonephritis]]
* Peg-asparaginase
* [[Autoimmune hemolytic anemia]]
* [[Intrathecal]] [[methotrexate]]
|-
* [[Intrathecal]] [[cytarabine]]
! align="center" style="background:#DCDCDC;" + |[[Hairy cell leukemia]]<ref name="pmid29110361">{{cite journal |vauthors=Troussard X, Cornet E |title=Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment |journal=Am. J. Hematol. |volume=92 |issue=12 |pages=1382–1390 |date=December 2017 |pmid=29110361 |pmc=5698705 |doi=10.1002/ajh.24936 |url=}}</ref><ref name="pmid29118233">{{cite journal |vauthors=Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H |title=Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology |journal=J Natl Compr Canc Netw |volume=15 |issue=11 |pages=1414–1427 |date=November 2017 |pmid=29118233 |doi=10.6004/jnccn.2017.0165 |url=}}</ref>
* [[Blinatumomab]] (bispecific [[T cell]] engager)
| align="left" style="background:#F5F5F5;" + |
* [[Inotuzumab ozogamicin|Inotuzumab]] ozogamycin (anti-CD22 antibody)
* Accumulation of small mature [[B cell]] lymphoid cells with abundant [[cytoplasm]] and "hairy" projections
* [[Tisagenlecleucel]] (chimeric antigen receptor T (CAR-T) cell therapy)
* [[BRAF]] mutation
* [[Stem cell transplant]]
| align="left" style="background:#F5F5F5;" + |
|
* Uncommon
* Sanctuary sites include the [[central nervous system]] ([[CNS]]) and [[testes]]<ref name="pmid23523389">{{cite journal| author=Inaba H, Greaves M, Mullighan CG| title=Acute lymphoblastic leukaemia. | journal=Lancet | year= 2013 | volume= 381 | issue= 9881 | pages= 1943-55 | pmid=23523389 | doi=10.1016/S0140-6736(12)62187-4 | pmc=3816716 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23523389  }} </ref>
* Median age 50 to 55 years old
* M >> F
* More common in Caucasians than Blacks
| align="left" style="background:#F5F5F5;" + |
* Exposures to [[ionizing radiation]], [[Pesticide|pesticides]], and farming
| align="left" style="background:#F5F5F5;" + |
* [[Muscle weakness|Weakness]] and [[fatigue]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Abdominal fullness
| align="left" style="background:#F5F5F5;" + |
* Normal
| align="center" style="background:#F5F5F5;" + | –
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + | +
[[Splenomegaly]]  
| align="left" style="background:#F5F5F5;" + |
* Asymptomatic
* Spontaneous [[splenic rupture]]
* [[Rash|Skin rash]]
* [[Ascites]]
* [[Pleural effusion]]
| align="left" style="background:#F5F5F5;" + |
* [[Cytopenia]]
* [[Leukocytosis]] in 10 to 20 percent
| align="left" style="background:#F5F5F5;" + |
* [[Pancytopenia]] with [[monocytopenia]] and circulating tumor cells characteristic of HCL
* Dry [[bone marrow]]
| align="left" style="background:#F5F5F5;" + |
* [[Azotemia]]
* Abnormal [[liver function tests]]
* [[Hypergammaglobulinemia]]
| align="left" style="background:#F5F5F5;" + |
* Analysis of [[Venous blood|peripheral blood]] + [[immunophenotyping]] by [[flow cytometry]]
| align="left" style="background:#F5F5F5;" + |
* [[Vasculitis]]
|-
! align="center" style="background:#DCDCDC;" + |Large granular lymphocytic leukemia<ref name="pmid28128670">{{cite journal |vauthors=Matutes E |title=Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options |journal=Expert Rev Hematol |volume=10 |issue=3 |pages=251–258 |date=March 2017 |pmid=28128670 |doi=10.1080/17474086.2017.1284585 |url=}}</ref><ref name="pmid28717070">{{cite journal |vauthors=Oshimi K |title=Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias |journal=Intern. Med. |volume=56 |issue=14 |pages=1759–1769 |date=2017 |pmid=28717070 |pmc=5548667 |doi=10.2169/internalmedicine.56.8881 |url=}}</ref>
| align="center" style="background:#F5F5F5;" + |
* Clonal proliferation of cytotoxic T cells
* Dysregulation of apoptosis through abnormalities in the Fas/Fas ligand pathway
| align="center" style="background:#F5F5F5;" + |
* Rare
* Median age 60 years
* M = F
| align="center" style="background:#F5F5F5;" + |
* Autoimmune diseases
* Lymphoproliferative disorders
| align="center" style="background:#F5F5F5;" + |
* [[Muscle weakness|Weakness]] and [[fatigue]]
| align="center" style="background:#F5F5F5;" + |↓
| align="center" style="background:#F5F5F5;" + |–
| align="center" style="background:#F5F5F5;" + |–
| align="center" style="background:#F5F5F5;" + |
* [[Fever]]
| align="center" style="background:#F5F5F5;" + |–
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
* Mostly asymptomatic
| align="center" style="background:#F5F5F5;" + |
* Modest lymphocytosis
* Neutropenia
* Anemia
* Thrombocytopenia
| align="center" style="background:#F5F5F5;" + |
* Large lymphocytes with a condensed round or oval nucleus, abundant pale basophilic cytoplasm, and small azurophilic granules
| align="center" style="background:#F5F5F5;" + |
* Multiple serological abnormalities including rheumatoid factor, antinuclear antibody, antiplatelet antibodies, antineutrophil antibodies, positive direct Coombs test, hyper- or hypogammaglobulinemia, monoclonal gammopathies, and elevated β2-microglobulin
| align="center" style="background:#F5F5F5;" + |
* Biopsy and flow cytometry + T-cell receptor gene rearrangement studies
| align="center" style="background:#F5F5F5;" + |
* Recurrent bacterial infection
|-
|-
|[[Chronic myelogenous leukemia|'''Chronic myeloid leukemia''']]
! align="center" style="background:#DCDCDC;" + |[[Chronic neutrophilic leukemia]]<ref name="pmid29512199">{{cite journal |vauthors=Elliott MA, Tefferi A |title=Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management |journal=Am. J. Hematol. |volume=93 |issue=4 |pages=578–587 |date=August 2018 |pmid=29512199 |doi=10.1002/ajh.24983 |url=}}</ref>
|
| align="center" style="background:#F5F5F5;" + |
* [[Translocation]] between [[Chromosome 9 (human)|chromosomes 9]] and [[Chromosome 22|22]]
* Mature granulocytic proliferation in the blood and marrow
* Creation of [[Bcr-abl|BCR-Abl]] [[gene]] product
* Point mutations in the CSF3R gene
|
| align="center" style="background:#F5F5F5;" + |
* Elevated [[white blood cell]] count
* Very rare
* Presence of [[white blood cell]] precursors at various stages of maturation
* M = F
* Presence of excess metamyelocytes, [[basophils]], [[eosinophils]], and [[band cells]]
| align="center" style="background:#F5F5F5;" + |
|
* Multiple myeloma
* [[Splenomegaly]]
| align="center" style="background:#F5F5F5;" + |
* [[Abdominal tenderness]]
* [[Muscle weakness|Weakness]] and [[fatigue]]
* [[Pallor]]
| align="center" style="background:#F5F5F5;" + |↓
* Evidence of [[infection]]
| align="center" style="background:#F5F5F5;" + |–
|
| align="center" style="background:#F5F5F5;" + |–
* [[Imatinib]]
| align="center" style="background:#F5F5F5;" + |
* [[Nilotinib]]
* [[Fever]]
* [[Dasatinib]]
| align="center" style="background:#F5F5F5;" + |–
* [[Bosutinib]]
| align="center" style="background:#F5F5F5;" + |
* [[Ponatinib]]
| align="center" style="background:#F5F5F5;" + | +
* [[Omacetaxine]]<ref name="pmid24516334">{{cite journal| author=Chen Y, Li S| title=Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia. | journal=Onco Targets Ther | year= 2014 | volume= 7 | issue=  | pages= 177-86 | pmid=24516334 | doi=10.2147/OTT.S41786 | pmc=3916637 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24516334  }} </ref>
The most common clinical finding
|
| align="center" style="background:#F5F5F5;" + |
* High response rate to [[tyrosine kinase inhibitors]]
* Pruritus
* Risk for development of T315I [[kinase]] domain [[mutation]]
* Gout
* Typically does not require [[stem cell transplant]]
| align="center" style="background:#F5F5F5;" + |
* Three phases include chronic, accelerated, and blast phase
* Peripheral blood neutrophilia (> 25 x 10<sup>9</sup>/L) with myeloid precursors (promyelocytes, myelocytes, metamyelocytes)
| align="center" style="background:#F5F5F5;" + |
* Toxic granulation in the [[Neutrophil|neutrophils]]
* Nuclear hypersegmentation
* Increased myeloid:erythroid ratio > 20:1
| align="center" style="background:#F5F5F5;" + |
* Elevated [[leukocyte alkaline phosphatase]]
| align="center" style="background:#F5F5F5;" + |
* WHO diagnostic criteria include leukocytosis of ≥ 25 x 109/L
* More than 80% neutrophils,  
* Less than 10% circulating neutrophil precursors with blasts
| align="center" style="background:#F5F5F5;" + |
* Poor prognosis
* Absence of the Philadelphia chromosome or a BCR/ABL fusion gene
|-
|-
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Demography
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Constitutional symptoms
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Weight
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Bleeding
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Abdominal Pain
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Vital sign
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Jaundice
! align="center" style="background:#4479BA; color: #FFFFFF;" + |LAP
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard diagnosis
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings
|-
|-
|[[Chronic lymphocytic leukemia|'''Chronic lymphocytic leukemia''']]<ref name="pmid28102226">{{cite journal| author=Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG et al.| title=Chronic lymphocytic leukaemia. | journal=Nat Rev Dis Primers | year= 2017 | volume= 3 | issue=  | pages= 16096 | pmid=28102226 | doi=10.1038/nrdp.2016.96 | pmc=5336551 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28102226  }} </ref>
|
* Chromosomal instability
* Sporadic [[mutations]]
* [[Infections]]
|
* Elevated absolute [[lymphocyte]] count (in all stages)
* Presence of >5000 clonal [[B cells]] per microliter in peripheral blood
* Anemia (in Rai stage III)
* [[Thrombocytopenia]] (in Rai stage IV)
|
* [[Lymph node enlargement]] in Rai stage I
* [[Splenomegaly]] in Rai stage II
* [[Hepatomegaly]] in Rai stage II
* [[Pallor]]
* [[Bleeding]]
|
* Fludarabine
* Cyclophosphamide
* Rituximab
* Obinutuzumab<ref name="pmid28182141">{{cite journal| author=Al-Sawaf O, Fischer K, Engelke A, Pflug N, Hallek M, Goede V| title=Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy. | journal=Drug Des Devel Ther | year= 2017 | volume= 11 | issue=  | pages= 295-304 | pmid=28182141 | doi=10.2147/DDDT.S104869 | pmc=5279834 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28182141  }} </ref>
* Ofatumumab
* Ibrutinib
* Venetoclax
|
* Associated with [[autoimmune hemolytic anemia]], which occurs in 10-25% of patients with CLL
* Associated with [[immune thrombocytopenia purpura]]
* Associated with [[pure red cell aplasia]]
* Treatment with corticosteroids or anti-leukemic therapy will correct the autoimmune complications of CLL
|}
|}



Revision as of 20:40, 11 January 2019

Acute lymphoblastic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Acute lymphoblastic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Bone X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute lymphoblastic leukemia differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute lymphoblastic leukemia differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute lymphoblastic leukemia differential diagnosis

CDC on Acute lymphoblastic leukemia differential diagnosis

Acute lymphoblastic leukemia differential diagnosis in the news

Blogs on Acute lymphoblastic leukemia differential diagnosis

Directions to Hospitals Treating Acute lymphoblastic leukemia

Risk calculators and risk factors for Acute lymphoblastic leukemia differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]

Overview

Acute lymphoblastic leukemia must be differentiated from other diseases such as acute myelogenous leukemia, hairy cell leukemia and malignant lymphoma.[1]

Differential diagnosis

The following table differentiates acute lymphoblastic leukemia from other leukemias that may present with similar clinical features such as fever, fatigue, weight loss, recurrent infections and elevated leukocyte counts. The following are the differentials:

Disease Etiology Clinical Manifestation Laboratory Findings Gold standard diagnosis Associated findings
Demography History Symptoms Signs
Constitutional symptoms Weight Bleeding Abdominal Pain Vital sign Jaundice LAP Hepatosplenomegaly Other CBC Histopathology Other
Acute myelogenous leukemia[2][3]
  • Clonal proliferation of malignant myeloid blast cells in the marrow
  • Genetic abnormalities t(8;21), inv(16), and t(15;17)
+ Rare Mild and asymptomatic NA
  • Persistent or frequent infections
  • Fatal within weeks or months if left untreated
Acute lymphoblastic leukemia[4][5]
  • Arrest of lymphoblasts
  • Chromosomal translocations: t(9;22) , t(12;21), t(5;14), t(1;19)
  • The most common form of cancer in children
  • Peak 2-5 years of age
  • Boys > girls
  • History of cancer
  • History of drug exposure
+ + + NA
  • CNS involvement
Chronic myelogenous leukemia[6][7]
  • Median age 50 years old
+ Abdominal fullness
  • Normal
+
Disease Etiology Demography History Constitutional symptoms Weight Bleeding Abdominal Pain Vital sign Jaundice LAP Hepatosplenomegaly Other CBC Histopathology Other Gold standard diagnosis Associated findings
Chronic lymphocytic leukemia[8]
  • The most common leukemia in adults in western countries
  • M > F
  • Median age 70 years old
+ + +

The most common abnormal finding

+
Hairy cell leukemia[9][10]
  • Accumulation of small mature B cell lymphoid cells with abundant cytoplasm and "hairy" projections
  • BRAF mutation
  • Uncommon
  • Median age 50 to 55 years old
  • M >> F
  • More common in Caucasians than Blacks
+ Abdominal fullness
  • Normal
± +

Splenomegaly

Large granular lymphocytic leukemia[11][12]
  • Clonal proliferation of cytotoxic T cells
  • Dysregulation of apoptosis through abnormalities in the Fas/Fas ligand pathway
  • Rare
  • Median age 60 years
  • M = F
  • Autoimmune diseases
  • Lymphoproliferative disorders
± +
  • Mostly asymptomatic
  • Modest lymphocytosis
  • Neutropenia
  • Anemia
  • Thrombocytopenia
  • Large lymphocytes with a condensed round or oval nucleus, abundant pale basophilic cytoplasm, and small azurophilic granules
  • Multiple serological abnormalities including rheumatoid factor, antinuclear antibody, antiplatelet antibodies, antineutrophil antibodies, positive direct Coombs test, hyper- or hypogammaglobulinemia, monoclonal gammopathies, and elevated β2-microglobulin
  • Biopsy and flow cytometry + T-cell receptor gene rearrangement studies
  • Recurrent bacterial infection
Chronic neutrophilic leukemia[13]
  • Mature granulocytic proliferation in the blood and marrow
  • Point mutations in the CSF3R gene
  • Very rare
  • M = F
  • Multiple myeloma
+

The most common clinical finding

  • Pruritus
  • Gout
  • Peripheral blood neutrophilia (> 25 x 109/L) with myeloid precursors (promyelocytes, myelocytes, metamyelocytes)
  • Toxic granulation in the neutrophils
  • Nuclear hypersegmentation
  • Increased myeloid:erythroid ratio > 20:1
  • WHO diagnostic criteria include leukocytosis of ≥ 25 x 109/L
  • More than 80% neutrophils,
  • Less than 10% circulating neutrophil precursors with blasts
  • Poor prognosis
  • Absence of the Philadelphia chromosome or a BCR/ABL fusion gene
Disease Etiology Demography History Constitutional symptoms Weight Bleeding Abdominal Pain Vital sign Jaundice LAP Hepatosplenomegaly Other CBC Histopathology Other Gold standard diagnosis Associated findings

References

  1. "National Cancer Institute".
  2. Saif A, Kazmi S, Naseem R, Shah H, Butt MO (August 2018). "Acute Myeloid Leukemia: Is That All There Is?". Cureus. 10 (8): e3198. doi:10.7759/cureus.3198. PMID 30410824. Vancouver style error: initials (help)
  3. Estey EH (April 2013). "Acute myeloid leukemia: 2013 update on risk-stratification and management". Am. J. Hematol. 88 (4): 318–27. doi:10.1002/ajh.23404. PMID 23526416.
  4. Sawalha Y, Advani AS (March 2018). "Management of older adults with acute lymphoblastic leukemia: challenges & current approaches". Int J Hematol Oncol. 7 (1): IJH02. doi:10.2217/ijh-2017-0023. PMC 6176956. PMID 30302234.
  5. Portell CA, Advani AS (April 2014). "Novel targeted therapies in acute lymphoblastic leukemia". Leuk. Lymphoma. 55 (4): 737–48. doi:10.3109/10428194.2013.823493. PMID 23841506.
  6. Saußele S, Silver RT (April 2015). "Management of chronic myeloid leukemia in blast crisis". Ann. Hematol. 94 Suppl 2: S159–65. doi:10.1007/s00277-015-2324-0. PMID 25814082.
  7. Eden RE, Coviello JM. PMID 30285354. Missing or empty |title= (help)
  8. Rai KR, Jain P (March 2016). "Chronic lymphocytic leukemia (CLL)-Then and now". Am. J. Hematol. 91 (3): 330–40. doi:10.1002/ajh.24282. PMID 26690614.
  9. Troussard X, Cornet E (December 2017). "Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment". Am. J. Hematol. 92 (12): 1382–1390. doi:10.1002/ajh.24936. PMC 5698705. PMID 29110361.
  10. Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H (November 2017). "Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology". J Natl Compr Canc Netw. 15 (11): 1414–1427. doi:10.6004/jnccn.2017.0165. PMID 29118233.
  11. Matutes E (March 2017). "Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options". Expert Rev Hematol. 10 (3): 251–258. doi:10.1080/17474086.2017.1284585. PMID 28128670.
  12. Oshimi K (2017). "Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias". Intern. Med. 56 (14): 1759–1769. doi:10.2169/internalmedicine.56.8881. PMC 5548667. PMID 28717070.
  13. Elliott MA, Tefferi A (August 2018). "Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management". Am. J. Hematol. 93 (4): 578–587. doi:10.1002/ajh.24983. PMID 29512199.

Template:WH Template:WS